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Abstract: Venous thromboembolism is a frequent and potentially life-threatening complication 
of orthopedic surgery. Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be 
effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty 
in the RECORD study program. Rivaroxaban has the potential to overcome the limitations of 
the current standards of care in the prevention of venous thromboembolism. XAMOS (Xarelto® 
in the prophylaxis of post-surgical venous thromboembolism after elective major orthopedic 
surgery of hip or knee) is an international, noninterventional, parallel-group study to gain insight 
into the safety (major bleeding, side effects) and effectiveness (prevention of symptomatic 
thromboembolic events) of rivaroxaban in daily clinical practice. XAMOS will follow 15,000 
patients after major orthopedic surgery in approximately 200 centers worldwide, with about 
7500 patients receiving rivaroxaban and about 7500 standard of care. XAMOS will supplement 
the clinical data obtained in the Phase III RECORD 1, 2, 3, and 4 trials in which rivaroxaban 
was shown to be superior for the primary efficacy endpoints, and with a safety profile similar 
to that of enoxaparin after hip or knee replacement surgery. XAMOS was started in 2009 and 
will complete recruitment and follow-up in 2011.
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Background
Venous thromboembolism is a frequent and potentially fatal complication in patients 
undergoing major hip or knee surgery. Without prophylaxis, patients have a 40%–60% 
risk of deep vein thrombosis detected by screening and a 1%–30% risk of pulmonary 
embolism (0.1%–7.5% fatal), depending on expositional and dispositional risks.1 
However, with routine use of thromboprophylaxis, fatal pulmonary embolism is 
uncommon, and symptomatic venous thromboembolism is reported in 1.3%–10% of 
patients within 3 months after surgery.1 Most symptomatic venous thromboembolism 
occurs after discharge from hospital and the risk continues for at least 2 months and is 
the most common cause for readmission of postsurgical patients to the hospital.2,3
Contemporary prophylaxis
For pharmacologic prophylaxis of venous thromboembolism in patients with total 
hip replacement, total knee replacement, and hip fracture surgery, three treatments 
are recommended in the current American College of Chest Physicians guidelines,4 
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ie, low molecular weight heparins, fondaparinux, and 
  adjusted-dose vitamin K antagonists. Prophylaxis is recom-
mended to continue for at least 10 days but, because of the 
prolonged risk, it may be extended for up to 35 days.4,5
While the parenteral agents, ie, low molecular weight 
heparin and fondaparinux, are effective, their use is limited 
by the requirement for subcutaneous injection. This may 
be regarded as desirable in the initial phase after surgery, 
because administration by health professionals ensures com-
plete coverage of the perioperative period without reliance 
on patient compliance. However, hesitance to self-inject 
(fearing the needle stick) and the potential negative impact 
on patient compliance have to be considered when patients 
are discharged from hospital. Because current hospitalization 
in many countries averages #4 days, this not only becomes 
important for extended prophylaxis but also for the manda-
tory initial phase of anticoagulation (1–10 days). A further 
concern in the use of low molecular weight heparins and 
likely also with fondaparinux is the potential for heparin-
induced thrombocytopenia. With low molecular weight 
heparin, heparin-induced thrombocytopenia is 10 times less 
frequent compared with unfractionated heparins, for which 
an incidence of 3% has been reported in patients following 
hip replacement surgery.6–8 The potential of fondaparinux to 
evoke heparin-induced thrombocytopenia is controversial,6,9 
and patients with potential heparin-induced thrombocytopenia 
have been successfully switched from unfractionated heparin 
or low molecular weight heparin to fondaparinux.10
Vitamin K antagonists are recommended by the guidelines 
based on a 44% reduction of deep vein thrombosis and 77% 
reduction of pulmonary embolism versus placebo.11 Vitamin 
K antagonists are considered to be less effective than low 
molecular weight heparin (relative risk 1.51 for total and 
proximal deep vein thrombosis)11 and fondaparinux in pre-
venting asymptomatic and symptomatic inhospital venous 
thromboembolism, with a slight but nonsignificant increase 
in surgical bleeding and wound hematoma. However, they are 
often used during the ambulatory phase of anticoagulation 
because their oral administration is perceived less of a barrier 
to use. Accordingly, for total hip replacement, adjusted-dose 
oral vitamin K antagonists with warfarin is a common form 
of thromboprophylaxis in North America.12 On the other hand, 
vitamin K antagonists are limited by a delayed onset of action, 
which in some cases makes bridging for 2–3 days into full 
anticoagulation with low molecular weight heparin necessary, 
and are also limited by the fact that vitamin K antagonists have 
a high interindividual variability, which is in part influenced 
by genetic polymorphism.13 In addition, they exhibit a high 
propensity for drug–drug and drug–food interactions, mak-
ing close supervision (International Normalized Ratio [INR] 
monitoring) with frequent dose adjustments necessary. While 
these prerequisites are generally met in clinical trials, where a 
considerable portion of patients are reported to be in the desir-
able INR range,11,14 clinical practice data have shown that the 
actual average proportion of patients in the desired INR range 
may be as low as 19%, despite using dosing nomograms.15
Rivaroxaban
Rivaroxaban (Xarelto®) is an oral direct factor Xa inhibitor. 
The oral bioavailability of rivaroxaban 10 mg is .90%, 
and peak plasma concentrations are achieved within 2.5 to 
4 hours.16,17 The clinical efficacy and safety of rivaroxaban 
10 mg once daily 6–8 hours postoperatively for the preven-
tion of venous thromboembolism after elective hip and 
knee arthroplasty has been established in the four random-
ized controlled trials of the REgulation of Coagulation in 
ORthopedic Surgery to Prevent DVT and PE (RECORD) 
study program (Table 1).5,18–20 In these studies, rivaroxaban 
was either compared with enoxaparin 40 mg once daily5,18,20 
or with 30 mg twice   daily.19 Rivaroxaban was more effec-
tive for the prevention of venous thromboembolism in all 
individual RECORD studies with no significant differences 
in major bleeding. A pooled analysis of data from RECORD 
1–3 (n = 9581) showed that rivaroxaban was more effective 
than enoxaparin in reducing the incidence of the composite 
of symptomatic venous thromboembolism and all-cause 
mortality at two weeks (0.4% versus 0.8%, respectively, odds 
ratio [OR] 0.44; 95% confidence interval [CI] 0.23–0.79; 
P = 0.005), and at the end of the planned treatment period 
(0.5% versus 1.3%, respectively; OR 0.38; 95% CI 0.22–0.62; 
P , 0.001).21 Based on these results, rivaroxaban is currently 
approved for the prophylaxis of venous thromboembolism 
in patients undergoing hip or knee arthroplasty in more than 
100 countries worldwide, and with a broad label for major 
orthopedic surgery to the lower limbs in some countries.
 Rivaroxaban has the potential to overcome the limitation of 
current prophylaxis regimens for venous   thromboembolism. 
It is orally available (resulting in a potential increase 
in compliance), has no propensity for development of 
heparin-induced thrombocytopenia, comes as a fixed dose 
independent of bodyweight, age, or gender, and has a broad 
therapeutic window. It should be used with caution in 
patients with severe impairment of renal function (creatinine 
clearance 15–30 mL/minute) and is not recommended in 
patients with a creatinine clearance below 15 mL/minute. 
With rivaroxaban, no routine monitoring of coagulation 
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factors or platelet counts is necessary. A perceived limitation 
of the new oral anticoagulants is the lack of specific 
  antidotes. In a recent study in healthy volunteers, prothrom-
bin complex concentrate has been shown to reverse the anti-
coagulant effect of rivaroxaban immediately and completely 
after application,22 but as promising as the results of this 
study are, the utility of prothrombin complex concentrate 
to reverse the action of rivaroxaban in the clinical setting 
will need to be evaluated in future studies in patients who 
are at risk of bleeding.
Study design
XAMOS (Xarelto® in the prophylaxis of post-surgical 
venous thromboembolism after elective major orthopedic 
surgery of hip or knee) is an international, noninterventional, 
open-label, controlled cohort study to document the effec-
tiveness and safety of rivaroxaban in daily clinical practice, 
involving approximately 7500 patients treated with rivaroxa-
ban and approximately 7500 using current standards in the 
prophylaxis of venous thromboembolism (low molecular 
weight heparins, fondaparinux, and   vitamin K antagonists). 
The study will be done in accordance with Good Epidemio-
logic Practice guidance. It was registered with clinicaltrials.
gov and received the identifier NCT00831714. The study 
was approved by the appropriate ethics committees prior to 
commencement in all countries, where an independent ethics 
committee or an independent review board was required. 
XAMOS is part of a risk management plan, agreed upon 
with the European Medicines Agency (EMA).
Objectives
The main objectives of this study are to collect real-life data 
on uncommon adverse events, bleeding events, symptomatic 
thromboembolic events, and all-cause mortality in patients 
treated with rivaroxaban or standard therapy. Further measures 
to be evaluated are treatment convenience, patient compliance, 
health care resource use, use in special patient populations, 
such as renal impairment, and the use of certain concomitant 
medications, eg, cytochrome P450 (CYP) 3A4-metabolized 
drugs and or inducers of CYP 3A4 or P-glycoprotein. In 
countries where the labeling is for major orthopedic surgery, 
data on patients receiving rivaroxaban for prophylaxis after 
hip fracture surgery will also be collected.
Physician and patient selection
Approximately 250 centers where more than 80 total hip 
or knee replacement surgeries per year are performed were 
invited to participate. The conduct of the study is supervised 
by an independent steering committee. Consecutive patients 
of either gender being at least 18 years old undergoing 
hip or knee arthroplasty (or hip fracture surgery where 
appropriate) and in whom a decision on pharmacologic 
Table 1 Results of the RECORD study program on hip and knee arthroplasty
Rivaroxaban Enoxaparin
% 95% CI % 95% CI
RECORD 118 (n = 4433) THR: Rivaroxaban 10 mg od postoperatively  
versus enoxaparin 40 mg od preoperatively;  
both for 35 days
Death 0.3 0.1–0.6 0.3 0.1–0.7
DVT* 0.8 0.4–1.3 3.4 2.6–4.4
Pulmonary embolism 0.3 0.1–0.6 0.1 ,0.1–0.4
Major bleeding 0.3 0.1–0.6 0.1 ,0.1–0.3
Primary endpoint 1.1 0.7–1.8 3.7 2.8–4.8
RECORD 25  (n = 2509) THR: Rivaroxaban 10 mg od postoperatively  
until day 31–39 versus enoxaparin 40 mg od  
preoperatively until day 10–14
Death 0.2 ,0.1–0.8 0.7 0.3–1.5
DVT* 1.6 0.9–2.7 8.2 6.4–10.2
Pulmonary embolism 0.1 ,0.1–0.6 0.5 0.1–1.2
Major bleeding ,0.1 ,0.1–0.5 ,0.1 ,0.1–0.5
Primary endpoint 2.0 1.2–3.1 9.3 7.5–11.5
RECORD 320 (n = 2531) TKR EU: Rivaroxaban 10 mg od postoperatively  
versus enoxaparin 40 mg od preoperatively;  
both for 10–14 days
Death 0.0 0.0–0.5 0.2 0.0–0.8
DVT* 9.6 7.7–11.8 18.2 15.7–20.9
Pulmonary embolism 0.0 0.0–0.3 0.5 0.1–1.2
Major bleeding 0.6 0.2–1.2 0.5 0.2–1.1
Primary endpoint 9.6 7.7–11.8 18.9 16.4–21.7
RECORD 419 (n = 2300) TKR US: Rivaroxaban 10 mg od versus  
enoxaparin 30 mg bid postoperatively;  
both for 10–14 days
Death 0.1 na 0.2 na
DVT 4.0 na 5.7 na
Pulmonary embolism 0.3 na 0.5 na
Major bleeding 0.7 0.3–1.2 0.3 0.1–0.7
Primary endpoint* 6.9 5.4–8.7 10.1 8.3–12.2
Note: *Significant differences.
Abbreviations: DVT, deep vein thrombosis; EU, European Union; THR, total hip replacement; TKR, total knee replacement; na, not available; od, once daily; bid, twice daily.
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venous thromboembolism prophylaxis has already been 
made will be documented. Patients have to provide 
written informed consent where necessary. To assess the 
representativeness of patients enrolled against the total 
population with hip or knee arthroplasty, a patient log will 
be completed by the surgeon that documents all patients 
receiving venous thromboembolism prophylaxis at that site 
and their study status (eg, enrolled, declined participation, 
or excluded). Basic information will be collected in case of 
nonparticipation (Figure 1).
Drug administration and initiation
Because this is a noninterventional study, the decision on the 
type, duration, and dose of drug used for venous thromboem-
bolism prophylaxis is solely at the discretion of the attending 
physician, and the specific prophylaxis is determined before 
patients enter the study.
Data acquisition
Data will be collected at the start of the venous throm-
boembolism prophylaxis, at hospital discharge, one week 
after completion of venous thromboembolism prophylaxis, 
and 3 months after surgery (see Table 2). Serious adverse 
events will be followed up until a final outcome is available. 
The participating centers collect the information using an 
electronic data capture system or a paper case report form 
collected by fax or mail. At collection, paper-based case 
report forms will be checked for completeness and missing 
information requested of the participating physician. After 
data entry, missing or implausible data will be queried 
and 5% of sites will be monitored in accordance with local 
regulatory provisions.
Statistical considerations
The main analysis is the comparison of the incidence rates 
of uncommon adverse events, bleeding events, symptomatic 
thromboembolic events, and all-cause mortality between the 
rivaroxaban group and the standard of care group comprising 
all nonrivaroxaban prophylactic venous thromboembolism 
drug regimens. A secondary analysis is a comparison between 
the rivaroxaban group and patients receiving low molecular 
weight heparins. For all adverse events and for each out-
come of interest, crude cumulative incidence rates will be 
calculated, together with 95% CI. Study subjects taking at 
least one dose of a venous thromboembolism prophylactic 
drug will be included in the safety analysis. This study 
Patient with hip or knee arthroplasty
physician decision on VTE prophylaxis
Physician documents all patients in log form
Patient will get rivaroxaban Patient will get standard of care
Any
empty
CRF?
Any
empty
CRF?
Patient informed consent Patient informed consent
Patient
signs
consent
Patient
signs
consent
Physician consecutively documents the first 10 eligible patients for each group
Documentation in log form
No
No
No
No
Yes Yes
Yes Yes
Figure 1 Study design of XAMOS.
Abbreviations: VTE, venous thromboembolism; CRF, case report form.
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population also includes patients treated with a prophylactic 
drug for venous thromboembolism but where surgery was 
cancelled after enrolment of the patient.
Sample size calculation
For the evaluation of the incidence of uncommon adverse 
events (which implies incidence rates between 0.1% and 
1%) the corresponding 95% CI range from 0.164 to 0.465 
percent points for 7500 patients (scenario A in Table 3). These 
values mark the minimum and maximum precisions which 
can be achieved. They are deemed to be sufficiently small 
to describe the incidence of uncommon adverse events in 
the study population. For subgroup analyses, the CI broaden 
because subgroups comprise fewer patients. However, for the 
expected subgroup sizes and incidences between 0.1% and 
1%, the corresponding 95% CI are also considered as reason-
ably narrow (scenario B in Table 3). In addition, the planned 
number of patients allows the detection with 95% power of 
a two-fold (or greater) increase of adverse event incidence 
in the rivaroxaban group compared with the standard of care 
drug therapy group of 0.55% (or higher) if the incidence rate 
is 0.55% (or higher) in the standard of care group. Uncommon 
adverse events with an incidence rate between 0.1% and 1% 
can be described with a 95% CI ranging from 0.164 to 0.465. 
This precision appears reasonably narrow, both in the overall 
study group, as well as in subgroup analyses.
Handling of confounders
In addition to reporting crude estimates, measures will be 
adjusted for baseline characteristics, such as age, gender, 
weight, smoking, alcohol use, and others. In addition, 
covariate adjustment using propensity score analysis will 
be performed.23 The propensity score will be computed for 
each subject by means of a logistic regression model, with 
treatment group as the dependent variable and all pretreat-
ment baseline characteristics as independent variables by 
type of intervention, ie, elective major surgery of hip or 
knee. Propensity scores are usually estimated using a large 
number of measured pretreatment covariates in a multivariate 
logistic regression model to predict exposure. The resulting 
summary of each study subject’s pretreatment covariates 
yields the expected individual’s propensity score, ie, the 
probability of receiving rivaroxaban or reference exposure. 
However, propensity scores can only be generated on covari-
ates collected. Although the study will collect some relevant 
pretreatment information, it will not be sufficient to provide 
risk estimates without confounding in association with the 
exposure of interest.
Outcomes assessment
All adverse events, including symptomatic thromboem-
bolic and bleeding events will be reported on the adverse 
event report form and coded using the latest release of the 
standardized Medical Dictionary for Regulatory Activities. 
Table 2 Scheduled procedures
Enrolment Surgery Hospital  
discharge
One week after  
end of therapy
Three months 
after surgery
Demographic data ×
Medical history ×
Surgical procedure
Antithrombotic therapy × × ×
Other venous thromboembolism prophylaxis ×
Health care resource questions × ×
Patient compliance ×
Assessment of therapy × ×
Concomitant medication × × × × ×
Adverse events × × × ×
Table  3  Width  of  95%  confidence  intervals  in  relation  to 
incidence rate
Scenario Incidence  
(%)
Patients  
observed (n)
95% CI (%) Width of   
95% CI
A 1.0 7500 [0.787–1.252] 0.465
0.106 7500 [0.046–0.210] 0.164
B 1.0 6000 [0.764–1.285] 0.521
1.0 5000 [0.743–1.316] 0.573
1.0 2000 [0.612–1.540] 0.928
1.0 1000 [0.481–1.831] 1.350
1.0 500 [0.326–2.318] 1.992
0.2 500 [0.005–1.109] 1.104
0.1 6000 [0.037–0.218] 0.181
0.1 5000 [0.033–0.233] 0.200
0.1 2000 [0.012–0.361] 0.349
0.1 1000 [0.003–0.556] 0.553
Note: Computation of CI based on Pearson–Clopper formula.
Abbreviation: CI, confidence interval.
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An adverse event is considered as treatment-emergent when 
it starts on or after the day of the first dose of a venous throm-
boembolism prophylactic drug and up to two days after the 
last dose. In case of a switch of the venous thromboembolism 
prophylactic treatment during the study course, any adverse 
event occurring within two days after the switch will be 
counted towards the previous treatment.
Thromboembolic events
Symptomatic thromboembolic events are identified using the 
Maintenance and Support Services Organization (MSSO) 
Standardized MedDRA Queries (SMQ) “thrombotic and 
embolic events.” For additional analyses, the events will be 
grouped into venous and arterial events. Given the noninter-
ventional nature of this study, no additional diagnostic mea-
sures for the detection or confirmation of thromboembolic 
events are mandated by the protocol.
Bleeding events
If a bleeding event occurs, an additional bleeding question-
naire for each reported event will be completed. Based on 
the data provided in the case report form and in the bleeding 
questionnaire the events will be adjudicated and differentiated 
as major and nonmajor bleeding events using the same adjudi-
cation rules used within the RECORD program. Additionally, 
bleeding events will be adjudicated according to the European 
Medicines Agency guideline on clinical investigations of 
medicinal products for prophylaxis of high intraoperative 
and postoperative venous thromboembolic risk.24
Discussion
XAMOS is a large noninterventional, open-label, observa-
tional study to document the real-life use of rivaroxaban in 
daily clinical practice in patients undergoing hip and knee 
arthroplasty. The choice of the noninterventional study 
design was based on several factors related to the specific 
aims of this study. First, rivaroxaban has been compared 
exclusively with enoxaparin, a current standard of care, in 
four large Phase III clinical trials (RECORD).5,18–20 Thus, the 
clinical efficacy of rivaroxaban and the positive benefit-risk 
ratio in comparison with enoxaparin is well established. 
Although having recruited more than 12,000 patients into 
the RECORD study program, the clinical experience is 
still limited compared with the established prophylaxis 
  modalities. Randomized controlled trials use strict inclusion 
and exclusion criteria, which narrow the population that can 
be studied in those trials, influencing the generalizability of 
the study results to the real world. Observational studies like 
XAMOS are specifically designed to be representative of the 
broad patient population treated in everyday care.
Furthermore, reporting of adverse events is highly reliable 
in clinical trials but, is less so in clinical practice, making an 
organized and well structured gathering of information neces-
sary to obtain further information on the clinical relevance 
of potential drug–drug interactions with regard to adverse 
events. Lastly, measuring compliance in Phase III clinical 
trials is usually misleading due to the tight nature of the study 
protocol and frequent monitoring. Vitamin K antagonists are 
a good example of how INR adjustments and bleeding com-
plications may differ from clinical trials to daily practice.25 
With this respect, the noninterventional study type used for 
XAMOS is suited to obtain data in practice on the actual 
use, dose regimen used, duration of use, and effectiveness 
and number of complications in routine care.
Limitations of study design
Because of the noninterventional, open-label study design 
and limitations inherent to observational studies,26 this study 
will not generate unbiased relative risk estimates or absolute 
incidence rates. It is acknowledged that biases of channeling 
and confounding by indication are present in observational 
studies, due to the lack of randomization and the open-label 
design, despite more advanced study designs and analytical 
methods, such as propensity score matching or adjustment 
for multiple covariates associated with drug use and the clini-
cal outcome.27 Propensity scores are estimated using a large 
number of measured pretreatment covariates in a multivariate 
logistic regression model to predict exposure. The resulting 
summary of each study subject’s pretreatment covariates 
yields the expected individual’s propensity score, ie, the 
probability of receiving rivaroxaban or reference exposure. 
Propensity score pairs suggest that pairs of, eg, rivaroxaban 
and low molecular weight heparin, mimic a randomized 
trial. Although the study will collect relevant pretreatment 
information, it will be insufficient to provide risk estimates 
without confounding in association with the exposure of 
interest. Furthermore, the number of different outcomes 
cannot be anticipated. Even though propensity score can bal-
ance observed baseline covariates between exposure groups, 
they do nothing to balance unmeasured characteristics and 
confounders. Therefore, as with all observational, noninter-
ventional studies, and unlike randomized controlled trials, 
propensity score analyses have the limitation that remaining 
unmeasured confounding may still be present.
Another important factor that must be considered is the 
so called “Weber effect.” This effect was first defined in 1984 
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by Weber,28 describing an increased adverse event reporting 
rate within the first 12–24 months after the introduction of a 
new drug to the market, due to increasing patient exposure 
and higher interest in the new drug, followed by a later fall 
in reporting when physicians become familiar with the new 
compound and the respective adverse event profile. A com-
parison of a new drug, like rivaroxaban, with older drugs with 
stable reporting and physicians who are experienced with 
their use in an open-label study might be misleading.
Conclusion
XAMOS is a large international, noninterventional study on 
the effectiveness, safety, and tolerability of rivaroxaban in 
daily clinical practice. This real-life data will be a valuable 
supplement to the data obtained during the four large Phase 
III trials in the RECORD program in which rivaroxaban has 
been shown to be superior to enoxaparin. The study was 
started in early 2009 and completed recruitment at the end of 
2011. First results of this study will be available in 2012.
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